Vasocontractile effects of alpha 2-adrenergic agonists associated with intracellular calcium release.
López
O
O
Escuela Superior de Medicina, IPN, Sección de Posgrado e Investigación, Plan de San Luis y Salvador Díaz Mirón s/n, Col. Casco de Sto Tomás, C.P. 11340 México, D.F., México.
Gil-Gastelum
O
O
Medina
R
R
Castillo
E F
EF
Castillo
C
C
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D000068438:Brimonidine Tartrate; D002118:Calcium / Q000378:metabolism*; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010109:Oxymetazoline / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014661:Vasoconstriction / Q000187:drug effects*
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D011810:Quinoxalines; D010656:Phenylephrine; D000068438:Brimonidine Tartrate; D010109:Oxymetazoline; D002118:Calcium